Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease

Clinical Neuropharmacology

Volumn 21, Issue 6, 1998, Pages 339-343

  Blanchet, Pierre J ^a   Fang, John ^a   Gillespie, Marjorie ^a   Sabounjian, LuAnn ^a   Locke, Kenneth W ^b   Gammans, Richard ^b   Mouradian, M Maral ^a   Chase, Thomas N ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b Interneuron Pharmaceuticals Inc   (United States)

Author keywords

D1 agonist; Dihydrexidine; Dopamine; Dyskinesia; Parkinson's disease

Indexed keywords

DIHYDREXIDINE; DOPAMINE 1 RECEPTOR; LEVODOPA;

ADULT; ARTICLE; CASE REPORT; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DYSKINESIA; FLUSHING; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; TACHYCARDIA;

ADULT; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; PHENANTHRIDINES; RECEPTORS, DOPAMINE D1; TREATMENT OUTCOME;

EID: 0031726938     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Marsden CD. Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol 1994;17(Suppl. 2):S32-44.
2. Creese I, Sibley DR, Hamblin MW, Leff SE. The classification of dopamine receptors: relationship to radioligand binding. Ann Rev Neurosci 1983;6:43-71.
3. Braun A, Fabbrini G, Mouradian MM, Serrati C, Barone P, Chase T.N. Selective D-1 dopamine receptor agonist treatment of Parkinson's disease. J Neural Transm 1987;68:41-50.
4. Bedard PJ, Boucher R. Effect of D1 receptor stimulation in normal and MPTP monkeys. Neurosci Lett 1989;104:223-8.
5. Clark D, White FJ. Review: D1 dopamine receptor - The search for a function: a critical evaluate of the D1/D2 dopamine receptor classification and its functional implications. Synapse 1987;1:347-88.
6. Mouradian MM, Heuser IJE, Baronti F, et al. Comparison of the clinical pharmacology of (-)NPA and levodopa in Parkinson's disease. J Neural Neurosurg Psychiat 1991;54:401-5.
7. Taylor JR, Lawrence MS, Redmond DE Jr, et al. Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist. J Pharmacol Exper Therap 1992;262:389-91.
8. Brewster WK, Nichols DE, Riggs RM, et al. trans-10, 11-dihydroxy-5,6,6a,7,8,12b-hexahydrobenzo[a]phenanthridine: a highly potent selective dopamine D1 full agonist. J Med Chem 1990; 33:1756-64.
9. Mottola DM, Brewster WK, Cook LL, Nichols DE, Mailman RB. Dihydrexidine, a novel full efficacy D1 dopamine receptor agonist. J Pharmacol Exper Therap 1992;262:383-93.
10. Darney KJ Jr, Lewis MH, Brewster WK, Nichols DE, Mailman RB. Behavioral effects in the rat of dihydrexidine, a high-potency, full-efficacy D1 dopamine receptor agonist. Neuropsychopharmacol 1991;5:187-95.
11. Elsworth JD, Lawrence MS, Roth RH, et al. D1 and D2 dopamine receptors independently regulate spontaneous blink rate in the vervet monkey. J Pharmacol Exper Therap 1991;259:595-600.
12. Johnson BJ, Peacock V, Schneider JS. Dihydrexidine, a full D1 dopamine receptor agonist, induces rotational asymmetry in hemiparkinsonian monkeys. Pharmacol Biochem Behav 1995;51:617-22.
13. Kohli JD, Horn PT, Glock D, Brewster WK, Nichols DE. Dihydrexidine: a new potent peripheral D1 receptor agonist. Eur J Pharmacol 1993;235:31-5.
14. Davis TL, Brughitta G, Baronti F, Mouradian MM. Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics. Neurology 1991;41:630-3.
15. Blanchet P, Bedard PJ, Britton DR, Kebabian JW. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys. J Pharmacol Exper Therap 1993;267:275-9.
16. Vermeulen RJ, Drukarch B, Sahadat MCR, Goosen C, Wolters EC, Stoof JC. The selective dopamine D1 receptor agonist. SKF 81297, stimulates motor behaviour of MPTP-lesioned monkeys. Eur J Pharmacol 1993;235:143-7.
17. Engber TM, Susel Z, Juncos JL, Chase TN. Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. Eur J Pharmacol 1989;168:291-8.
18. Rascol O, Blin O, Descombes S, et al. ABT-431, a selective D1 agonist has efficacy in patients with Parkinson's disease. Neurology 1997;48:A269-70.
19. Hahn RA, Wardell JR Jr, Sarau HM, Ridley PT. Characterization of the peripheral and central effects of SK&F 82526, a novel dopamine receptor agonist. J Pharmacol Exper Therap 1982;223:305-13.
20. Yatsu T, Arai Y, Takizawa K., et al. Renal effect of YM435, a new dopamine D1 receptor agonist, in anesthetized dogs. Eur J Pharmacol 1997;322:45-53.
21. Amenta F. Light microscope autoradiography of dopamine receptor subtypes. Clin Exper Hypertension 1997;19:27-41.
22. Durrieu G, Senard JM, Rascol O, et al. Blood pressure and plasma catecholamines in never-treated parkinsonian patients: Effect of a selective D1 agonist (CY 208-243). Neurology 1990;40: 707-9.
23. Amenta F, Gallo P, Rossodivita A, Ricci A. Radioligand binding and autoradiographic analysis of dopamine receptor in the human heart. Naunyn Schmied Arch Pharmacol 1993;347:147-54.
24. Habuchi Y, Tanaka H, Yamamoto T, Komori T, Nishio M, Yoshimura M. The mechanisms underlying heart stimulation by dopamine, with special reference to direct and indirect β adrenoreceptor stimulation. Clin Exper Hypertension 1997;19:141-54.